SCLX:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 1.11

Change

-0.01 (-0.89)%

Market Cap

N/A

Volume

0.46M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-28 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

-0.69 (-0.87%)

USD 249.50B
AMGN Amgen Inc

+2.39 (+0.72%)

USD 177.35B
SNY Sanofi ADR

+0.38 (+0.67%)

USD 145.64B
BIIB Biogen Inc

-2.26 (-1.14%)

USD 29.85B
GRFS Grifols SA ADR

+0.15 (+1.65%)

USD 6.95B
AMRN Amarin Corporation PLC

+0.02 (+3.13%)

USD 0.24B
MIRA MIRA Pharmaceuticals, Inc. Com..

+0.01 (+0.75%)

USD 0.02B
SCLXW Scilex Holding Company

-0.01 (-4.19%)

N/A

ETFs Containing SCLX

BTEC 0.00 % 0.42 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -45.59% 10% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.59% 10% F 17% F
Trailing 12 Months  
Capital Gain -62.63% 20% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -62.63% 20% F 14% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -33.27% 20% F 9% A-
Dividend Return -33.27% 20% F 9% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 38.27% 30% F 47% F
Risk Adjusted Return -86.93% 20% F 9% A-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector